TDNA ETF — T. Rowe Price Biotech ETF

T. Rowe Price Biotech ETF (TDNA)

TDNA is an ETF. its expense ratio is 0.55%.

T. Rowe Price Biotech ETF is an actively managed equity ETF that seeks long-term capital growth in biotechnology companies. Typical holdings 60-120 names. Expense ratio 0.55%. Began trading on Nasdaq 09/17/2026. Sibling T. Rowe Price equity ETFs distribute annually; the fund has not yet paid a distribution.

TDNA key facts

Issuer

T. Rowe Price

Asset type

ETF

Asset class

Equity

Inception date

09/17/2026

Expense ratio

0.55%

Distribution frequency

Annual

Last close

$24.97 (as of 2026-09-18)

Average volume

205.0

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: T. Rowe Price; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TDNA risks and drawbacks

Payments are annual, so cash flow is lumpy versus a monthly fund.

Who may consider TDNA — and who may not

It is a weaker fit for investors who need monthly cash flow (TDNA pays annual); investors hunting double-digit covered-call yields. This is educational context, not a recommendation to buy or sell.

Frequently asked questions

More securities from T. Rowe Price.